TY  - JOUR
AU  - Chaparro, M
AU  - Garre, A
AU  - Guerra-Veloz, M F
AU  - Vazquez-Moron, J M
AU  - De-Castro, M L
AU  - Leo, E
AU  - Rodriguez, E
AU  - Carbajo, A Y
AU  - Riestra, S
AU  - Jimenez, I
AU  - Calvet, X
AU  - Bujanda, L
AU  - Rivero, M
AU  - Gomollon, F
AU  - Benitez, J M
AU  - Bermejo, F
AU  - Alcaide, N
AU  - Gutierrez, A
AU  - Mañosa, M
AU  - Iborra, M
AU  - Lorente, R
AU  - Rojas-Feria, M
AU  - Barreiro-de Acosta, M
AU  - Kolle, L
AU  - Van-Domselaar, M
AU  - Amo, V
AU  - Argüelles, F
AU  - Ramirez, E
AU  - Morell, A
AU  - Bernardo, D
AU  - Gisbert, J P
PY  - 2019
DO  - 10.1093/ecco-jcc/jjz070
UR  - http://hdl.handle.net/10668/13818
T2  - Journal of Crohn's & colitis
AB  - To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. Patients under Remicade® who were in clinical remission with standard dosage at study entry were...
LA  - en
PB  - Oxford University Press
KW  - Crohn’s disease
KW  - Inflammatory bowel disease
KW  - Remicade®
KW  - Sup > CT-P13
KW  - Switch
KW  - Ulcerative colitis
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Cohort Studies
KW  - Female
KW  - Follow-Up Studies
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Recurrence
KW  - Retrospective Studies
TI  - Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease.
TY  - research article
VL  - 13
ER  -